Global Rett Syndrome Market: Industry Analysis & Outlook (2017-2025)
Rett syndrome is a rare genetic neurological disorder. This genetic disorder affects females exclusively due to the presence of X chromosome, and is rarely seen in boys. Male children are less prone to this disorder because boys with mutations in MECP2 hardly survive till birth. Changes in MECP2 typically occur during spermatogenesis, and such changes are usually on the paternal copy of the X-chromosome.
The symptoms of Rett syndrome generally occur after 12 months of birth and include signs like slow growth, loss of normal movement and coordination, abnormal hands and eyes movements, and breathing problems. Other drastic symptoms also develop with age. This disorder generally occurs in stages and fourth stage is said to be its last stage. Rett syndrome has no cure and is often treated with off-label drugs which prove to give no relief to the affected patient. Few pharmaceuticals companies are realizing the need for target specific drugs and many therapeutics are being developed, which are in their clinical phases.
The global Rett syndrome market will grow over the years driven by increase in female population, rising spending on public healthcare programs, and increasing global healthcare expenditure. The major trends and developments of the market include efforts to use gene therapy to rectify this neurological disorder, development of new drugs and use of more efficient technologies. However, growth of the market is challenged by factors like high cost of treatment and high R&D expenditure.
The report “Global Rett Syndrome Market: Industry Analysis & Outlook (2017-2025)” analyzes the development of this market, with focus on Sarizotan drug and its market opportunities. The major players are: Newron Pharmaceuticals, Neurem Pharmaceuticals Limited, Anavex Life Sciences Corp., Neuroloxis, and Edison Pharmaceuticals.
The symptoms of Rett syndrome generally occur after 12 months of birth and include signs like slow growth, loss of normal movement and coordination, abnormal hands and eyes movements, and breathing problems. Other drastic symptoms also develop with age. This disorder generally occurs in stages and fourth stage is said to be its last stage. Rett syndrome has no cure and is often treated with off-label drugs which prove to give no relief to the affected patient. Few pharmaceuticals companies are realizing the need for target specific drugs and many therapeutics are being developed, which are in their clinical phases.
The global Rett syndrome market will grow over the years driven by increase in female population, rising spending on public healthcare programs, and increasing global healthcare expenditure. The major trends and developments of the market include efforts to use gene therapy to rectify this neurological disorder, development of new drugs and use of more efficient technologies. However, growth of the market is challenged by factors like high cost of treatment and high R&D expenditure.
The report “Global Rett Syndrome Market: Industry Analysis & Outlook (2017-2025)” analyzes the development of this market, with focus on Sarizotan drug and its market opportunities. The major players are: Newron Pharmaceuticals, Neurem Pharmaceuticals Limited, Anavex Life Sciences Corp., Neuroloxis, and Edison Pharmaceuticals.
1. MARKET OVERVIEW
1.1 Rett Syndrome
1.2 Signs and Symptoms
1.3 Stages of Rett Syndrome
1.4 Causes of Rett Syndrome
1.5 Diagnosis and Treatment
2. GLOBAL MARKET ANALYSIS
2.1 Global Rett Syndrome Prevalence
2.1.1 Global Rett Syndrome Prevalence by Region
2.1.2 Global Rett Syndrome Prevalence Share by Region
2.2 Global Rett Syndrome Incidence
2.3 Global Sarizotan Drug Market
2.3.1 Global Sarizotan Drug Market Forecast by Value
2.3.2 Global Sarizotan Drug Market Forecast by Region
3. REGIONAL ANALYSIS
3.1 Europe’s Rett Syndrome Patient Volume Forecast
3.2 Europe’s Rett Syndrome Population with Breathing Disorder
3.3 Europe’s Rett Syndrome Patient Diagnosis Rate
3.4 Europe Sarizotan Drug Market
3.4.1 Europe’s Sarizotan Drug Market Forecast by Value
3.4.2 Europe’s Sarizotan Drug Treatment by Patient Volume
3.5 The US Rett Syndrome Patient Volume Forecast
3.6 The US Rett Syndrome Population with Breathing Disorder
3.7 The US Rett Syndrome Patient Diagnosis Rate
3.8 The US Sarizotan Drug Market
3.8.1 The US Sarizotan Drug Market Forecast by Value
3.8.2 The US Sarizotan Drug Treatment by Patient Volume
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Increasing Female Population Worldwide
4.1.2 Rising Spending on Public Health Programs for Females
4.1.3 Increased Spending on Medicines
4.1.4 Increasing Global Healthcare Expenditure
4.2 Trends and Developments
4.2.1 Gene Therapy for Rett Syndrome
4.2.2 Development of New Drugs
4.2.3 Development of More Efficient and Advanced Technology
4.3 Issues and Challenges
4.3.1 High Cost of Treatment
4.3.2 High R&D Costs
4.3.3 Drug Progress Challenges in Developing Countries
5. COMPETITIVE LANDSCAPE
5.1 Global Rett Syndrome Market
5.1.1 Major Companies Comparison by Drug Segments
5.1.2 Comparison by Market Cap
6. COMPANY PROFILES
6.1 Newron Pharmaceuticals
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Neuren Pharmaceuticals Limited
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Anavex Life Sciences Corp.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Neuroloxis
6.4.1 Business Overview
6.5 Edison Pharmaceuticals
6.5.1 Business Overview
1.1 Rett Syndrome
1.2 Signs and Symptoms
1.3 Stages of Rett Syndrome
1.4 Causes of Rett Syndrome
1.5 Diagnosis and Treatment
2. GLOBAL MARKET ANALYSIS
2.1 Global Rett Syndrome Prevalence
2.1.1 Global Rett Syndrome Prevalence by Region
2.1.2 Global Rett Syndrome Prevalence Share by Region
2.2 Global Rett Syndrome Incidence
2.3 Global Sarizotan Drug Market
2.3.1 Global Sarizotan Drug Market Forecast by Value
2.3.2 Global Sarizotan Drug Market Forecast by Region
3. REGIONAL ANALYSIS
3.1 Europe’s Rett Syndrome Patient Volume Forecast
3.2 Europe’s Rett Syndrome Population with Breathing Disorder
3.3 Europe’s Rett Syndrome Patient Diagnosis Rate
3.4 Europe Sarizotan Drug Market
3.4.1 Europe’s Sarizotan Drug Market Forecast by Value
3.4.2 Europe’s Sarizotan Drug Treatment by Patient Volume
3.5 The US Rett Syndrome Patient Volume Forecast
3.6 The US Rett Syndrome Population with Breathing Disorder
3.7 The US Rett Syndrome Patient Diagnosis Rate
3.8 The US Sarizotan Drug Market
3.8.1 The US Sarizotan Drug Market Forecast by Value
3.8.2 The US Sarizotan Drug Treatment by Patient Volume
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Increasing Female Population Worldwide
4.1.2 Rising Spending on Public Health Programs for Females
4.1.3 Increased Spending on Medicines
4.1.4 Increasing Global Healthcare Expenditure
4.2 Trends and Developments
4.2.1 Gene Therapy for Rett Syndrome
4.2.2 Development of New Drugs
4.2.3 Development of More Efficient and Advanced Technology
4.3 Issues and Challenges
4.3.1 High Cost of Treatment
4.3.2 High R&D Costs
4.3.3 Drug Progress Challenges in Developing Countries
5. COMPETITIVE LANDSCAPE
5.1 Global Rett Syndrome Market
5.1.1 Major Companies Comparison by Drug Segments
5.1.2 Comparison by Market Cap
6. COMPANY PROFILES
6.1 Newron Pharmaceuticals
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Neuren Pharmaceuticals Limited
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Anavex Life Sciences Corp.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Neuroloxis
6.4.1 Business Overview
6.5 Edison Pharmaceuticals
6.5.1 Business Overview
LIST OF CHARTS
Global Rett Syndrome Prevalence Share by Region (2016)
Global Sarizotan Drug Market Forecast by Value (2018-2025)
Global Sarizotan Drug Market Forecast by Region (2025)
Europe’s Rett Syndrome Patient Volume Forecast (2016-2025)
Europe’s Rett Syndrome Population with Breathing Disorder (2016-2025)
Europe’s Rett Syndrome Patient Diagnosis Rate (2016-2025)
Europe’s Sarizotan Drug Market Forecast by Value (2018-2025)
Europe’s Sarizotan Drug Treatment by Patient Volume (2018-2025)
The US Rett Syndrome Patient Volume Forecast (2016-2025)
The US Rett Syndrome Population with Breathing Disorder (2016-2025)
The US Rett Syndrome Patient Diagnosis Rate (2016-2025)
The US Sarizotan Drug Market Forecast by Value (2018-2025)
The US Sarizotan Drug Treatment by Patient Volume (2018-2025)
Global Female Population (2012-2016)
Global Spending on Medicines (2010-2020E)
Total Spending on Medicines in the US (2012-2016)
Global Healthcare Expenditure (2012-2016)
Comparison by Market Cap (2016)
Newron Pharmaceuticals Revenue and Net Loss (2012-2016)
Neuren Pharmaceuticals Operating Revenue and Net Loss (2013-2016)
Anavex Life Sciences Corp. Operating Expenses and Net Loss (2014-2016)
List of Tables
Global Rett Syndrome Prevalence by Region (2016)
Global Rett Syndrome Incidence (2016)
Major Drugs for Rett Syndrome in their Development Phases (2016)
Major Companies Comparison by Drug Segments (2016)
Clinical Pipeline of Newron Pharmaceuticals (2016)
Neuren Pharmaceuticals Limited’s Product Pipeline (2016)
Anavex Life Sciences Corp.’s Clinical Pipeline with Drug Candidates (2016)
Neuroloxis’s Drug Developments (2016)
Edison Pharmaceutical’s Drug Pipeline (2016)
Edison Pharmaceutical’s Clinical Developments
Global Rett Syndrome Prevalence Share by Region (2016)
Global Sarizotan Drug Market Forecast by Value (2018-2025)
Global Sarizotan Drug Market Forecast by Region (2025)
Europe’s Rett Syndrome Patient Volume Forecast (2016-2025)
Europe’s Rett Syndrome Population with Breathing Disorder (2016-2025)
Europe’s Rett Syndrome Patient Diagnosis Rate (2016-2025)
Europe’s Sarizotan Drug Market Forecast by Value (2018-2025)
Europe’s Sarizotan Drug Treatment by Patient Volume (2018-2025)
The US Rett Syndrome Patient Volume Forecast (2016-2025)
The US Rett Syndrome Population with Breathing Disorder (2016-2025)
The US Rett Syndrome Patient Diagnosis Rate (2016-2025)
The US Sarizotan Drug Market Forecast by Value (2018-2025)
The US Sarizotan Drug Treatment by Patient Volume (2018-2025)
Global Female Population (2012-2016)
Global Spending on Medicines (2010-2020E)
Total Spending on Medicines in the US (2012-2016)
Global Healthcare Expenditure (2012-2016)
Comparison by Market Cap (2016)
Newron Pharmaceuticals Revenue and Net Loss (2012-2016)
Neuren Pharmaceuticals Operating Revenue and Net Loss (2013-2016)
Anavex Life Sciences Corp. Operating Expenses and Net Loss (2014-2016)
List of Tables
Global Rett Syndrome Prevalence by Region (2016)
Global Rett Syndrome Incidence (2016)
Major Drugs for Rett Syndrome in their Development Phases (2016)
Major Companies Comparison by Drug Segments (2016)
Clinical Pipeline of Newron Pharmaceuticals (2016)
Neuren Pharmaceuticals Limited’s Product Pipeline (2016)
Anavex Life Sciences Corp.’s Clinical Pipeline with Drug Candidates (2016)
Neuroloxis’s Drug Developments (2016)
Edison Pharmaceutical’s Drug Pipeline (2016)
Edison Pharmaceutical’s Clinical Developments
